Alkylating-induced hypermutation in pancreatic neuroendocrine tumours.
1/5 보강
Pancreatic neuroendocrine tumours (PanNET) represent the most chemosensitive subtype of NET, with alkylating agents being the mainstay treatment for advanced-stage disease.
APA
Taboada RG, Torrezan GT, Riechelmann RP (2025). Alkylating-induced hypermutation in pancreatic neuroendocrine tumours.. BMJ oncology, 4(1), e000814. https://doi.org/10.1136/bmjonc-2025-000814
MLA
Taboada RG, et al.. "Alkylating-induced hypermutation in pancreatic neuroendocrine tumours.." BMJ oncology, vol. 4, no. 1, 2025, pp. e000814.
PMID
41244370 ↗
Abstract 한글 요약
Pancreatic neuroendocrine tumours (PanNET) represent the most chemosensitive subtype of NET, with alkylating agents being the mainstay treatment for advanced-stage disease. However, disease progression remains inevitable and presents significant clinical challenges. Advances in tumour molecular profiling have facilitated a deeper understanding of the genomic landscape of PanNET, with the aim of guiding therapeutic strategies. Although actionable mutations and elevated tumour mutational burden (TMB) are exceedingly rare in PanNET, they may offer novel therapeutic opportunities. Emerging evidence suggests that treatment with alkylating agents can induce a hypermutator phenotype in a subset of PanNET, characterised by a marked increase in TMB. This genomic evolution may enhance neoantigen load and thereby potentiate responsiveness to immune checkpoint inhibition. This mini review explores hypermutation in PanNET, with a focus on alkylating-induced changes, and considers the potential of immunotherapy in this context.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.